4-CHLORO-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE

4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is a key synthetic intermediate used in the design and preparation of ruxolitinib-vorinostat conjugate derivatives, which possess dual inhibitory activity against Janus kinase (JAK) and histone deacetylase (HDAC) . As a versatile chemical building block, 4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine plays an essential role in the synthesis of ruxolitinib (INCB028050/LY3009104), a potent inhibitor of JAK1 and JAK2 used in the treatment of myelofibrosis and polycythemia vera . 4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine also serves as Baricitinib Impurity 31 (designated in pharmacopeial standards), making it an indispensable reference standard for analytical method development, method validation (AMV), and quality control (QC) applications for Abbreviated New Drug Applications (ANDA) . The trimethylsilyl group within 4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine enhances the compound‘s stability and compatibility under various reaction conditions, allowing for efficient manipulation and derivatization, further broadening its utility across diverse chemical synthesis workflows .

Product Parameters

Synthetic Route

4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is prepared via SEM protection of commercially available 4-chloro-7H-pyrrolo[2,3-d]pyrimidine, using sodium hydride as the base and 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) as the alkylating reagent.

Procedure (from literature-validated protocol) :

1.In an inert atmosphere (nitrogen or argon), dissolve 4-chloro-7H-pyrrolo[2,3-d]pyrimidine in anhydrous DMF.

2.Add sodium hydride (NaH) and allow the mixture to stir at ambient temperature to deprotonate the N-7 position.

3.Cool the reaction mixture to 0 °C.

4.Slowly add a solution of 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) dissolved in DMF to the cooled mixture.

5.Stir the resulting mixture at room temperature until full conversion is achieved (approximately 1–2 hours).

6.Quench the reaction by adding glacial acetic acid to neutralize excess base.

7.Dilute the reaction mixture with pure water.

8.Extract the product with ethyl acetate.

9.Wash the combined organic layers with saturated brine.

10.Concentrate the organic layer under reduced pressure to remove the solvent.

11.Purify the crude product by silica gel column chromatography using an appropriate eluent system (e.g., ethyl acetate/hexane).

12. The product is obtained as a colorless oil that crystallizes upon addition of a seed crystal, yielding white crystals.

Application Scenarios

1.Ruxolitinib API Manufacturing

As the pivotal building block for ruxolitinib (Jakafi®), this SEM-protected intermediate undergoes sequential deprotection, amination, and functionalization to introduce the JAK-specific side chain required for JAK1/JAK2 inhibition. Generic manufacturers require consistent, high-purity material to ensure API equivalence and regulatory compliance.

2.Baricitinib API Manufacturing

Similarly, this compound is the key intermediate for baricitinib (Olumiant®), proceeding through a parallel synthetic route that installs the baricitinib-specific side chain at the 4-position after SEM deprotection .

3.Impurity 31 Reference Standard

This compound is the designated Baricitinib Impurity 31 in pharmacopeial standards. Analytical laboratories, CROs, and generic manufacturers use it as a certified reference standard for impurity profiling, method validation (AMV), quality control (QC) testing, and forced degradation studies for baricitinib API and finished drug product .

4.JAK/HDAC Dual Inhibitor Research

4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is used in the design and preparation of ruxolitinib-vorinostat conjugate derivatives, which are investigated for their potential as dual inhibitors of JAK and HDAC — a promising strategy for treating cancers and inflammatory disorders where both pathways are dysregulated .

5.Directed Lithiation and C‑6 Functionalization

The SEM group permits ortho-lithiation at the C‑6 position using organolithium bases, followed by electrophilic quenching with aldehydes, ketones, or iodine to generate 6-substituted pyrrolopyrimidine derivatives. This capability enables SAR studies for optimizing kinase inhibitor potency and selectivity .

6.Nucleophilic Aromatic Substitution (SNAr) Library Synthesis

The electron-deficient pyrimidine ring bearing a chlorine leaving group at the 4-position undergoes SNAr reactions with primary and secondary amines, alkoxides, and thiols. The resulting 4-substituted products serve as scaffolds for constructing compound libraries targeting a broad range of kinases beyond JAK, including BTK, EGFR, and CDK families.

7.ANDA / NDA Regulatory Filing Support

For generic manufacturers filing Abbreviated New Drug Applications (ANDA) for ruxolitinib or baricitinib, this intermediate (or its impurity standard form) is a critical component of the analytical method validation package — used in system suitability testing, specificity studies, and impurity profiling as part of ICH Q2(R1)-compliant method validation.

8.Analytical Method Development & Validation

Used for developing, validating, and transferring HPLC and UPLC methods for pyrrolopyrimidine-based APIs. Supports selectivity assessment, LOD/LOQ determination, accuracy and precision studies, and robustness testing for commercial quality control.

9.Process Development & Scale‑Up

Pharmaceutical process chemists use this intermediate for reaction optimization, impurity mapping, and development of scalable commercial manufacturing routes for JAK inhibitors. Cosperpharm provides characterization data and process support for seamless scale‑up from laboratory to pilot plant.

10.Forced Degradation Studies

Used as an impurity marker in forced degradation studies (oxidative, thermal, photolytic, hydrolytic, and basic/acidic stress conditions) to monitor the formation of process-related impurities and confirm the stability-indicating power of analytical methods for JAK inhibitor formulations.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for 4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine that meets the rigorous expectations of both pharmaceutical intermediate manufacturing and reference standard applications:

Thorough analytical characterization. Each production batch undergoes multi‑technique analytical release testing: HPLC purity (≥98%, standard grade, with full chromatographic traceability and integration summary), appearance verification (white to off-white solid), and where applicable, ¹H NMR and MS confirmation of molecular identity. Physical property verification (refractive index, density reference) is conducted in accordance with established specifications.

Full batch traceability with retention samples. From raw material procurement (4-chloro-7H-pyrrolo[2,3-d]pyrimidine and SEM-Cl sourced from qualified suppliers) through SEM protection, purification, crystallization, drying, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

Stability monitoring program. Cosperpharm conducts ongoing stability studies under recommended storage conditions for this compound: long‑term storage at 2–8 °C under inert atmosphere, with accelerated stability studies (40 °C / 75 % RH) conducted on representative batches. Stability summaries are updated regularly, with full data packages available to support customer regulatory submissions. Shelf life: 2 years when stored as recommended.

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. For customers preparing ANDA or NDA filings for ruxolitinib, baricitinib, or other pyrrolopyrimidine-based APIs, Cosperpharm provides DMF-ready documentation packages, method validation reports, stability data, and custom quality agreements upon request.

Customer‑initiated quality audits. Qualified customers are welcome to audit Cosperpharm‘s manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit. ISO compliance documentation is available upon request.

Contact us

If you're looking for the seller of 4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine, contact us now.